Risk of Supply Disruptions Due to Product Defects
First written in FY2017. 6 of 7 entries say "Restated". Latest entry: FY2026.
5 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「We conduct sufficient testing before commercializing our products and work to maintain and control their quality. However, if any of our products were to have a defect, corrective action at the contract manufacturer could take time, during which product supply could be temporarily halted, potentially affecting our business performance.」
The company reiterates its testing and quality control before commercialization, as well as the risks of delays in corrective action and supply stoppages when defects occur. - FY2025RestatedAnnual report
「We conduct sufficient testing before commercializing our products and work to maintain and control their quality. However, if any of our products were to have a defect, corrective action at the contract manufacturer could take time, during which product supply could be temporarily halted, potentially affecting our business performance.」
The company reiterates its testing and quality control before commercialization, as well as the risks of delays in corrective action and supply stoppages when defects occur. - FY2024RestatedAnnual report
「We conduct sufficient testing before commercializing our products and work to maintain and control their quality. However, if any of our products were to have a defect, corrective action at the contract manufacturer could take time, during which product supply could be temporarily halted, potentially affecting our business performance.」
The company reiterates its testing and quality control before commercialization, as well as the risks of delays in corrective action and supply stoppages in the event of defects. - FY2020RestatedAnnual report
「We conduct sufficient testing before commercializing our group's products and work to maintain and control their quality. However, if any of our group's products were to have a defect, corrective action at the contract manufacturer could take time, during which product supply could be temporarily halted, potentially affecting our group's business performance.」
The company reiterates its testing and quality control before commercialization, as well as the risks of delays in corrective action and supply stoppages in the event of defects. - FY2019RestatedAnnual report
「We conduct sufficient testing before commercializing our group's products and work to maintain and control their quality. However, if any of our group's products were to have a defect, corrective action at the contract manufacturer could take time, during which product supply could be temporarily halted, potentially affecting our group's business performance.」
While conducting testing and quality control before commercialization, the company continues to describe the risks of delays in corrective action and supply stoppages in the event of defects. - FY2018RestatedAnnual report
「We conduct sufficient testing before commercializing our group's products and work to maintain and control their quality. However, if any of our group's products were to have a defect, corrective action at the contract manufacturer could take time, during which product supply could be temporarily halted, potentially affecting our group's business performance.」
While conducting testing and quality control before commercialization, the company continues to describe the risks of delays in corrective action and supply stoppages in the event of defects. - FY2017First statedAnnual report
「We conduct sufficient testing before commercializing our group's products and work to maintain and control their quality. However, if any of our group's products were to have a defect, corrective action at the contract manufacturer could take time, during which product supply could be temporarily halted, potentially affecting our group's business performance.」
While stating its policy of conducting testing and quality control before commercialization, the company identifies delays in corrective action and supply stoppages in the event of defects as risks.